CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
Net Asset Value(s)
Par Pacific Announces Private Placement of $500 Million of Senior Notes
Safe Pro’s Edge AI Battlefield Threat Detection Selected by U.S. Army for Upcoming Force-on-Force Combat Exercise